Category - Developments

PharmaJet Logo

PharmaJet sponsor study published in The Lancet

A Phase 3 clinical study sponsored by PharmaJet’s partner, Zydus Lifesciences, featuring ZyCoV-D, the world’s first plasmid-DNA vaccine approved for use in humans and delivered by the PharmaJet Tropis Intradermal needle...

Qualigen Therapeutics

Qualigen acquires majority stake in NanoSynex

Qualigen Therapeutics (NASDAQ:QLGN) completed the acquisition of a majority stake in NanoSynex, an Israeli-based developer of next generation diagnostics technology. In a statement, Michael Poirier, chairman and CEO of...

Profound Medical

Profound Medical insiders add to holdings 

Profound Medical (NASDAQ:PROF; TSX:PRN) independent lead director, Brian Ellacott, and chairman and CEO, Arun Menawat, purchased additional shares of Profound on Nasdaq after the company’s 2022 first quarter blackout...